225 related articles for article (PubMed ID: 23775562)
1. Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity.
Fukuda Y; Takenaka K; Sparreboom A; Cheepala SB; Wu CP; Ekins S; Ambudkar SV; Schuetz JD
Mol Pharmacol; 2013 Sep; 84(3):361-71. PubMed ID: 23775562
[TBL] [Abstract][Full Text] [Related]
2. Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state.
Sauna ZE; Nandigama K; Ambudkar SV
J Biol Chem; 2004 Nov; 279(47):48855-64. PubMed ID: 15364914
[TBL] [Abstract][Full Text] [Related]
3. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Gupta A; Zhang Y; Unadkat JD; Mao Q
J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
[TBL] [Abstract][Full Text] [Related]
4. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Washington CB; Duran GE; Man MC; Sikic BI; Blaschke TF
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):203-9. PubMed ID: 9803961
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters.
Srinivas RV; Middlemas D; Flynn P; Fridland A
Antimicrob Agents Chemother; 1998 Dec; 42(12):3157-62. PubMed ID: 9835508
[TBL] [Abstract][Full Text] [Related]
6. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.
Zhang L; Gorset W; Washington CB; Blaschke TF; Kroetz DL; Giacomini KM
Drug Metab Dispos; 2000 Mar; 28(3):329-34. PubMed ID: 10681378
[TBL] [Abstract][Full Text] [Related]
7. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Schütt M; Zhou J; Meier M; Klein HH
J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
[TBL] [Abstract][Full Text] [Related]
9. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
[TBL] [Abstract][Full Text] [Related]
10. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.
Cihlar T; Ray AS; Laflamme G; Vela JE; Tong L; Fuller MD; Roy A; Rhodes GR
Antivir Ther; 2007; 12(2):267-72. PubMed ID: 17503669
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M
Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
[TBL] [Abstract][Full Text] [Related]
12. The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene.
Abla N; Chinn LW; Nakamura T; Liu L; Huang CC; Johns SJ; Kawamoto M; Stryke D; Taylor TR; Ferrin TE; Giacomini KM; Kroetz DL
J Pharmacol Exp Ther; 2008 Jun; 325(3):859-68. PubMed ID: 18364470
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 protease inhibitors. A review for clinicians.
Deeks SG; Smith M; Holodniy M; Kahn JO
JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
[TBL] [Abstract][Full Text] [Related]
14. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
15. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.
Imaoka T; Kusuhara H; Adachi M; Schuetz JD; Takeuchi K; Sugiyama Y
Mol Pharmacol; 2007 Feb; 71(2):619-27. PubMed ID: 17110501
[TBL] [Abstract][Full Text] [Related]
16. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.
Patick AK; Boritzki TJ; Bloom LA
Antimicrob Agents Chemother; 1997 Oct; 41(10):2159-64. PubMed ID: 9333041
[TBL] [Abstract][Full Text] [Related]
17. HIV protease inhibitors stimulate hepatic triglyceride synthesis.
Lenhard JM; Croom DK; Weiel JE; Winegar DA
Arterioscler Thromb Vasc Biol; 2000 Dec; 20(12):2625-9. PubMed ID: 11116063
[TBL] [Abstract][Full Text] [Related]
18. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
Lucia MB; Rutella S; Leone G; Vella S; Cauda R
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):321-30. PubMed ID: 11468419
[TBL] [Abstract][Full Text] [Related]
19. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.
Ford J; Meaden ER; Hoggard PG; Dalton M; Newton P; Williams I; Khoo SH; Back DJ
J Antimicrob Chemother; 2003 Sep; 52(3):354-8. PubMed ID: 12917239
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).
Mizuno N; Takahashi T; Kusuhara H; Schuetz JD; Niwa T; Sugiyama Y
Drug Metab Dispos; 2007 Nov; 35(11):2045-52. PubMed ID: 17682070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
